Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05245682 · ClinicalTrials.gov registry record · Early Phase 1

Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer

A Early Phase 1 study of Head and Neck Carcinoma of Unknown Primary and Locally Advanced Head and Neck Squamous Cell Carcinoma, sponsored by Emory University.

Active
Registry status
Early Phase 1
Development phase
10
Enrollment target
1
Study location

NCT05245682 is a Early Phase 1 study of Head and Neck Carcinoma of Unknown Primary and Locally Advanced Head and Neck Squamous Cell Carcinoma that is active but no longer recruiting, run by Emory University. The registered enrollment target is 10 participants, below the 71-participant average among 6 other Head and Neck Carcinoma of Unknown Primary trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05245682, a Early Phase 1 study of Head and Neck Carcinoma of Unknown Primary and Locally Advanced Head and Neck Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Emory University.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This early-phase trial tests the safety and side effects of a tolinapant given together with radiation therapy in treating patients with head and neck cancer for which the patient has not received treatment in the past (previously untreated), has spread to nearby tissue or lymph nodes (locally advanced) and cannot receive cisplatin (cisplatin-ineligible). Tolinapant may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving tolinapant and radiation therapy may kill more tumor cells.

Conditions Studied

Head and Neck Carcinoma of Unknown Primary Locally Advanced Head and Neck Squamous Cell Carcinoma Locally Advanced Hypopharyngeal Squamous Cell Carcinoma Locally Advanced Laryngeal Squamous Cell Carcinoma Locally Advanced Oropharyngeal Squamous Cell Carcinoma Locally Advanced Nasopharyngeal Squamous Cell Carcinoma

Interventions

  • RADIATION Radiation Therapy
  • DRUG Tolinapant

Study Locations (1)

Georgia

  • Emory University/Winship Cancer Institute - Atlanta

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2022-02-17
Est. Completion 2026-07-21
Phase Early Phase 1

Sponsor

Emory University

1,208 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05245682

The ClinicalTrials.gov registry entry for NCT05245682 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 71-participant average among 6 other Head and Neck Carcinoma of Unknown Primary trials with a reported enrollment target (86% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Head and Neck Carcinoma of Unknown Primary appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.

NCT05245682 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT05245682 about?

NCT05245682 is a clinical study titled "Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer". This early-phase trial tests the safety and side effects of a tolinapant given together with radiation therapy in treating patients with head and neck cancer for which the patient has not received treatment in the past (previously untreated), has spread to nearby tissue or lymph nodes (locally advan...

What is the current status of trial NCT05245682?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2022-02-17. Estimated completion is 2026-07-21.

What conditions does trial NCT05245682 study?

This clinical trial studies the following conditions: Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma.

What interventions are being tested in trial NCT05245682?

The interventions under investigation include: Radiation Therapy (RADIATION), Tolinapant (DRUG).

Who is sponsoring clinical trial NCT05245682?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05245682 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Carcinoma of Unknown Primary

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Carcinoma of Unknown Primary

All registered trials for this condition

Locally Advanced Head and Neck Squamous Cell Carcinoma

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.